Analyst firms · Oppenheimer · CAPR

Oppenheimer CAPR price target and rating history

Capricor Therapeutics Inc. (CAPR) · Health Care

Oppenheimer rates Capricor Therapeutics Inc. (CAPR) Outperform with a $54 price target, as of its latest action on Aug 25, 2026. It has published 3 rating actions on CAPR since May 2024, including 1 upgrade and 1 downgrade. Across 6 firms with a CAPR price target in the last 12 months, the median target is $23. Oppenheimer's $54 is 135% above that.

Current rating

Outperform

Price target

$54

Median target, all firms

$23

Actions on CAPR

3

Oppenheimer price target on CAPR

Every Oppenheimer rating on CAPR

• Aug 25, 2026
  UpgradeOppenheimer upgrades to Outperform from Perform, price target $54
• Jul 30, 2026
  DowngradeOppenheimer downgrades to Perform from Outperform
• May 17, 2024
  InitiateOppenheimer starts coverage at Outperform, price target $14

How other firms rate CAPR

Each firm's latest rating and stated target in the last 12 months.

Questions about Oppenheimer and CAPR

What is Oppenheimer's price target for CAPR?

Oppenheimer's latest stated price target for Capricor Therapeutics Inc. (CAPR) is $54, from its action on Aug 25, 2026.

What is Oppenheimer's rating on CAPR?

Oppenheimer rates CAPR Outperform, a bullish rating, as of Aug 25, 2026.

When did Oppenheimer last change its view on CAPR?

On Aug 25, 2026, Oppenheimer upgrades to Outperform from Perform, price target $54.

How does Oppenheimer's CAPR target compare with other analysts?

Across 6 firms with a CAPR price target in the last 12 months, the median target is $23. Oppenheimer's $54 is 135% above that.

More CAPR rating histories

• B. Riley Securities3
• Piper Sandler3
• Cantor Fitzgerald3
• H.C. Wainwright3

All Oppenheimer ratingsCAPR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.